News
US FDA accepts for review GSK’s NDA for linerixibat to treat cholestatic pruritus in patients with PBC: London, UK Tuesday, June 3, 2025, 11:00 Hrs [IST] GSK plc announced the U ...
Drugmaker GSK revealed on Monday that a new drug application for its linerixibat asset had been accepted for review by the US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback